
AC Immune SA
ACIUNASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$2.73
Day High
$2.78
Day Low
$2.65
Prev. Close
$2.75
VolumeShares traded today.
291.70K
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$270.72M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-3.22
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$4.00
52W LowLowest price over the past 52 weeks.
$1.60
50D MAAverage closing price over the last 50 trading days.
$2.92
200D MAAverage closing price over the last 200 trading days.
$2.96
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
-6.7%1M
-9.2%6M
-8.3%YTD
-20.8%1Y
+55.6%About
Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.
www.acimmune.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade ACIU
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.